Recombinant human serum albumin (OsrHSA) has emerged as a big innovation in the sector of biopharmaceuticals, presenting promising progress throughout many clinical and industrial apps. With its structural similarity to Normally derived human serum albumin, OsrHSA offers a safer, more trustworthy substitute for therapeutic use, specifically in drug